Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab in Hidradenitis Suppurativa
NCT06326476Phase 1Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of siplizumab in hidradenitis suppurativa (HS) (3 arms), sponsored by University of Alabama at Birmingham. Primary endpoint: Change in inflammatory lesion counts at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
siplizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06326476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326476.